Although NDP‐αMSH is currently used to treat adult patients with EPP, there remains a high medical need for new effective, safe and more conveniently administered treatments for EPP and XLP, especially for pediatric/adolescent patients who have had no options to date. This evidence concerns the gene NDP and autosomal erythropoietic protoporphyria.